FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
All XRAYs
Article : Overview of pancreatic cancer treatment options
Most relevant for: People with pancreatic cancer
This review looks at current strategies for pancreatic cancer care and potential future therapies. (posted 7/28/21)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Test score may predict which prostate cancer patients can safely skip combined therapy
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Men with advanced prostate cancer
This study shows that a test score that estimates the aggressiveness of a person’s prostate cancer may also identify the best treatment for patients. (posted 7/9/21)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Cancer risks of people with inherited PALB2 mutations
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: people with inherited PALB2 mutations
In the largest study of people with inherited PALB2 mutations to date, the gene was linked to increased lifetime risk of breast cancer in women and men, ovarian and pancreatic cancer but not prostate or colorectal cancer. (posted 7/1/21)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Women can have safe pregnancies after breast cancer treatment
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Women who have had breast cancer who are considering pregnancy.
In a large analysis of all published studies to date, most women who become pregnant after breast cancer treatment had safe pregnancies, with no increase in their cancer recurrence risk. Infants of mothers treated for breast cancer were more likely to have low birth weight, preterm birth and small size at birth but there was no increase in birth defects. Breast cancer survivors who became pregnant had a similar risk of recurrence and survival as survivors who did not become pregnant. (posted 6/24/21)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Birth control pills may offer long-term protection against endometrial and ovarian cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People concerned about endometrial, ovarian or breast cancer risk
A large study showed that birth control pills may protect against endometrial and ovarian cancers, even years after use was discontinued. (posted 6/1/21)
Este artículo está disponible en español.
Read MoreUpdate : FDA allows testing of a vaccine designed to prevent breast cancer
Most relevant for: Patients with non-metastatic triple-negative breast cancer at high risk of recurrence.
Scientists have been working for many years to develop a vaccine that will prevent breast cancer. The FDA recently announced that the first clinical trial to test a preventive breast cancer vaccine can begin. This vaccine is the result of over a decade of research in animals and human cells. While researchers will first test the vaccine in women who have breast cancer, they hope to use this vaccine in the future to prevent breast cancer. (posted 5/25/21)
THIS INFORMATION HAS BEEN UPDATED on 10/12/2021: The clinical trial discussed in this XRAY review has begun recruiting participants. Researchers hope to enroll 24 patients with non-metastatic triple-negative breast cancer. The trial is being conducted at the Cleveland Clinic in Cleveland, Ohio. More information on this trial can be found here.
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsUpdate : Immunotherapy dostarlimab gains FDA approval for treatment of recurrent and advanced endometrial cancer
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with recurrent or advanced endometrial cancer
The FDA has given accelerated approval for the immunotherapy agent dostarlimab (Jemperli) to treat recurrent and advanced endometrial cancer that has a biomarker called mismatch repair deficiency (dMMR). This adds a new treatment option for people with recurrent or advanced endometrial cancer. (posted 5/18/21)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Daily high-dose aspirin taken for at least 2 years reduces the risk of colorectal cancer but not other cancers in people with Lynch syndrome
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with Lynch syndrome
Research has shown that daily aspirin use can reduce the risk of colon and other cancers. The Cancer Prevention Program 2 (CaPP2) study looked at the effect of daily aspirin in patients with Lynch syndrome. After 10 years of follow-up, the results showed that taking daily aspirin for two years reduced the frequency of colon cancer in patients with Lynch syndrome, and importantly, did not result in an increase in side-effects or complications. No benefit was seen for other Lynch syndrome-related cancers, including endometrial cancer. (5/17/21)
Este artículo está disponible en español.
Read MoreUpdate : Cancer disparities: Colorectal cancer in African Americans
Most relevant for: African Americans concerned about colorectal cancer
The American Association for Cancer Research (AACR) released a 2020 report about cancer disparities among racial and ethnic groups in the United States. In this XRAY review, we highlight data from the report about the burden of colorectal cancer in African Americans, who have the highest rates of diagnosis and death related to the disease among all racial and ethnic groups. (Posted 4/27/21)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Expanded access to Medicaid coverage under the Affordable Care Act is linked to reduced cancer mortality
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People with breast, colorectal or lung cancer.
In 2014 the Affordable Care Act expanded Medicaid coverage. How did this affect healthcare for cancer patients? This study shows that deaths from breast, colorectal and lung cancer are lower in states that chose to expand Medicaid compared to states that did not. Early diagnosis was linked to lower death rates. This suggests that increased healthcare access may lead to earlier cancer detection and better outcomes, including lower mortality. (3/31/2021)
Este artículo está disponible en español.
Read More